Amarin - The Science Of Lipid Therapy (Seite 34)

[gergeo]

Ich habe eine ganze Weile als Stillhalter Amarin-puts verkauft, mit großem Erfolg. Heute wird mir der strike von 6 angedient werden, ich werden den put nicht glattstellen und somit ab morgen neuer Aktienbesitzer von Amarin sein. Insgesamt halte ich die Chancen, meine 6 $ alsbald wieder zu sehen, für gut. Take profit, werde also ab und an bei euch reinschauen.

[Magnetfeldfredy]

Sollen Sie, das Potential bleibt:

Why Amarin Stock Is Sinking Today
The company's CEO announced his retirement.
Keith Speights
(TMFFishBiz)
Apr 13, 2021 at 11:39AM
Author Bio
What happened

Shares of Amarin (NASDAQ:AMRN) were 10.4% lower as of 11:20 a.m. EDT on Tuesday. The decline came after the drugmaker announced that John Thero plans to retire as president and CEO effective Aug. 1.
So what

It's not unusual for changes at the CEO level to cause a biotech stock to fall, especially when the CEO's departure is unexpected. But in this case, there don't appear to be any yellow flags with Thero stepping down.
Wood blocks showing an organizational structure with fingers holding the top block

Image source: Getty Images.

Thero was CEO for the last seven years and he's now 60, an age when many people retire. Amarin has already named his successor: Karim Mikhail, senior vice president and head of commercial for Europe, will take the reins in August.

Perhaps the main reason for Amarin's shares sinking today is that Thero's exit could lower the prospects of any merger and acquisition deals over the near term. Amarin is viewed by some as a potential buyout target.
Now what

The main things to watch with Amarin are the company's launch of Vascepa in Europe and the anticipated approval of the drug in China later this year. Mikhail's track record of more than 20 years at Merck, including leading the big drugmaker's commercial operations for its lipid drugs, seems to make him a good fit to take the baton from Thero in overseeing these efforts.

[lobberland]

Die Shorts setzen hier aber jetzt Dampf auf den Kessel 😤😤

[Magnetfeldfredy]

New CEO at Amarin to facilitate continued growth, says Piper Sandler 20:53 AMRN Piper Sandler analyst Yasmeen Rahimi keeps her Overweight rating and $19 price target on Amarin after the company announced that Karim Mikhail would succeed John Thero as CEO later this year. The Street was surprised by the announcement, the analyst tells investors in a research note, but she believes that his deep commercial expertise will facilitate Amarin's continued growth, especially ahead of VAZKEPA's E.U. launch in Q3 of this year.

Read more at:
https://thefly.com/n.php?id=3281222

[Magnetfeldfredy]

Hier stimmt Vieles, nur nicht der Kurs!
Big pharma shortet Amarin über Hedgefonds bis zum "Geht nicht mehr" um Amarin billigst zu übernehmen und dann Milliarden mit Vascepa weltweit zu generieren!
Du hast Recht, wir brauchen Zeit, nur dass ich schon über 10 Jahre dabei bin....und bleibe bis zur Übernahme!

[Stevo0815]

Ja, irgendetwas stimmt hier nicht. Es kann nur noch besser werden. Hier ist Geduld gefordert.

[Magnetfeldfredy]

Ich kann nur noch sagen, was für eine manipulierte Scheißaktie........😡
EU-Zulassung, China vor der Tür, USA Markt bleibt auch mit 500 Millionen pro Jahr und dann ein Kurs zum Kotzen!🤠

[lobberland]

Wir sind dann jetzt so ziemlich an dem Punkt angelangt, wo der Kurs sich von der Realität abkoppelt... dann kann der Buyout jetzt bitte kommen...

[bernie55]

Antwort auf Beitrag Nr.: 67.789.964 von Magnetfeldfredy am 13.04.21 09:57:36

Erste Liveperformance dann am 20.04.21 auf dem Reuters-Event - als NOCH nicht CEO.




Die Vita liest sich auf den ersten Blick schon ' mal gut:
Mikhail kommt zu Amarin von THEODON, einer globalen kommerziellen Strategieberatung, die er 2018 gegründet hat und wo er als Chief Executive Officer tätig war. Davor war er 22 Jahre lang bei Merck tätig, in einer Karriere, die sieben verschiedene Länder auf drei Kontinenten umfasste. Zuletzt war er Global Commercial Leader für Mercks 4 Milliarden Dollar schweres Lipid-Franchise. Davor war Herr Mikhail auch Chief Marketing Officer für Europa, den Nahen Osten und Afrika sowie Chief Operating Officer für Schwellenländer. Während seiner Zeit bei Merck leitete Mikhail die erfolgreiche Markteinführung von Dutzenden von Produkten, darunter Ezetimib und verschiedene Moleküle in den Bereichen Diabetes, Bluthochdruck, Immunologie und Onkologie.

[Magnetfeldfredy]

Neuer CEO, hoffentlich bald höhere Kurse!


Amarin Announces CEO Succession Plan

Amarin Corporation plc
Mon, April 12, 2021, 10:30 PM

John Thero to Retire as President and CEO on August 1, 2021

Board Appoints Karim Mikhail, Current SVP and Head of Commercial for Europe, as Successor

DUBLIN, Ireland and BRIDGEWATER, N.J., April 12, 2021 (GLOBE NEWSWIRE) -- Amarin Corporation plc (NASDAQ:AMRN) today announced that John F. Thero, 60, has informed the board of directors of his plan to retire as president and chief executive officer, effective August 1, 2021. He will also step down from the board at that time. The board has appointed Karim Mikhail, 50, Amarin’s senior vice president and head of commercial for Europe, to succeed Mr. Thero as the company’s next president and chief executive officer. Mr. Mikhail will join the board upon his effective date. Mr. Thero will continue to provide his guidance and expertise to the company in an advisory capacity through the end of 2021.

Mr. Mikhail joined Amarin in 2020 from THEODON, a global commercial strategy consultancy he founded in 2018. Prior to this, Mr. Mikhail spent more than 20 years at Merck, where from 2014 to 2018 he served as global commercial leader for Merck’s $4 billion lipid franchise, overseeing P&L and leading the worldwide launch of ezetimibe with the IMPROVE-IT study indication. In this role, he was responsible for reversing the business’ decline in the U.S. market and globally, accelerating revenue by an additional $380 million through the launch of ATOZET and driving EBITDA growth through international expansion. Prior to that, Mr. Mikhail led the successful commercial launch of dozens of products, including ezetimibe and various molecules in diabetes, hypertension, immunology, and oncology, and served as Merck’s chief marketing officer for Europe, Middle East and Africa and chief operating officer for emerging markets. At Amarin, Mr. Mikhail has been responsible for preparing commercialization of the company’s lead product in Europe, for which regulatory approval was received on March 30, 2021.

Dr. Lars Ekman, Chairman of Amarin’s Board of Directors, commented, “After 12 years at Amarin, and the last seven as CEO, John has decided now is the right time to announce his retirement. We owe enormous gratitude to John as under his leadership roles, with the support of the entire Amarin team, the company has completed multiple successful clinical trials, launched its lead product VASCEPA® (icosapent ethyl) in the United States, and has initiated its international expansion plans, including commercialization in Europe following the recent marketing authorization of VAZKEPA from the European Commission. John and the entire board have taken a thoughtful approach to succession planning designed to ensure that Amarin is best positioned to both continue its progress in the United States and accelerate its growth trajectory globally. The board has been increasingly impressed with Karim’s strategic and operational capabilities, and his clear passion for VASCEPA and vision for continuing Amarin’s progress worldwide make him the clear choice to succeed John. We look forward to an exciting new chapter for the highly capable Amarin team under Karim’s leadership.”

“While announcing my retirement is a bittersweet moment for me, I have every confidence in Amarin and its outstanding employees who are dedicated to the patients and shareholders we serve,” said Mr. Thero. “2021 is a pivotal year for Amarin as we continue to develop markets for our important drug, VASCEPA. As the first-and-only drug approved by each of the U.S. FDA, European Commission, and Health Canada for treatment of the studied high-risk patients with persistent cardiovascular risk after statin therapy, we are proud of our role in ushering in a new era in cardiovascular care. With our unique therapeutic solution and deep bench of internal talent, I believe that now is an ideal time to transition leadership to Karim as we work to realize Amarin’s full potential. Since Karim joined Amarin last year, he has proven himself to be an invaluable member of the leadership team and a true partner to me as we prepare for the commercialization of VAZKEPA in Europe. I am excited to continue working closely with him and the board to facilitate a successful transition over the coming months.”

Mr. Mikhail stated, “I joined Amarin last year because I was inspired by the company’s entrepreneurial spirit in addressing such a large unmet medical need and the potential to set a new standard of cardiovascular care. I am honored to take on this new role. We have an unparalleled product with outstanding evidence, positive efficacy and safety profile, and tremendous momentum with our near-term European launch plans and expected commercial approval in China near the end of 2021. Amarin’s team is first rate and I am excited to build upon the strong commercial progress in the United States. I look forward to working with John, the board and the entire Amarin team as we capture the significant growth opportunities ahead.”

About Karim Mikhail
Mr. Mikhail, 50, joined Amarin in July 2020, and currently serves as senior vice president and head of commercial for Europe where he has responsibility for the company’s commercialization of VAZKEPA in Europe. He was previously with Merck for 22 years, in seven different countries, spanning three continents, where he held positions of increasing responsibility, including as global commercial leader for Merck’s $4 billion lipid franchise and chief marketing officer for Europe, Middle East and Africa and chief operating officer for emerging markets. Mr. Mikhail led THEODON, a global commercial strategy consultancy he founded in 2018.

Mr. Mikhail is a pharmacist by training and holds a master’s degree in biopharmaceutical marketing and management from the graduate school of business in Paris, École Supérieure de Commerce de Paris (ESCP).

About Amarin
Amarin is an innovative pharmaceutical company leading a new paradigm in cardiovascular disease management. From our scientific research foundation to our focus on clinical trials, and now our commercial expansion, we are evolving and growing rapidly. Amarin has offices in Bridgewater, New Jersey in the United States, Dublin in Ireland, and Zug in Switzerland as well as commercial partners and suppliers around the world. We are committed to rethinking cardiovascular risk through the advancement of scientific understanding of the impact on society of significant residual risk that exists beyond traditional therapies, such as statins for cholesterol management.

About Cardiovascular Risk
Cardiovascular disease is the number one cause of death in the world. In the United States alone, cardiovascular disease results in 859,000 deaths per year.1 And the number of deaths in the United States attributed to cardiovascular disease continues to rise. In addition, in the United States there are 605,000 new and 200,000 recurrent heart attacks per year (approximately 1 every 40 seconds). Stroke rates are 795,000 per year (approximately 1 every 40 seconds), accounting for 1 of every 19 U.S. deaths. In aggregate, in the United States alone, there are more than 2.4 million major adverse cardiovascular events per year from cardiovascular disease or, on average, 1 every 13 seconds.